Clinical Trial Update: Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of different oral doses of BAY94-8862 in Japanese subjects with type 2 diabetes and diabetic nephropathy (AR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• BAY94-8862

Snippet

Sponsor: Bayer | Conditions: Diabetic Nephropathies | Phase 2 | Status: COMPLETED